Cervical Cancer

A supplemental biologics license application has been granted priority review by the FDA, which seeks a full approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer that progressed on or following frontline therapy.

For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.

The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.

The 12-month overall survival rates were 48.7% and 35.3% with tisotumab vedotin and chemotherapy, respectively, among patients with recurrent or metastatic cervical cancer.

Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.

Cancer screening tests may not extend life expectancy; however, they still are valuable for public health.

Many Americans with health insurance are not fully covered for frontline procedures to treat lymphedema—a debilitating condition that often affects patients with cancer.

Liquid biopsies helped determine which patients with cervical cancer were at a high risk of recurrence following chemoradiation.

Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.

Patient navigation services increased the rates of breast, cervical, and colorectal cancer screenings 6-fold amongst women living in rural communities.

A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

Cervical cancer and precancers have decreased in recent years, thanks to the HPV vaccine.

The phase III AIM2CERV trial investigating axalimogene filolisbac (AXAL) in patients with cervical cancer has been placed on partial clinical hold by the FDA.

The presence of HPV-16 and -18 were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia (CIN) in women under the age of 30, study says.

The Food and Drug Administration (FDA) approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to expand its use in women and men aged 27 to 45 years.

New guidelines issued by the US Preventive Services Task Force (USPSTF) recommend for women aged 30 to 65 years at average risk for cervical cancer to choose to receive a Pap smear alone every 3 years, screening with the high-risk human papillomavirus test alone, or cotesting every 5 years.

The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.

Pelvic IMRT causes less GI, GU toxicities than standard pelvic radiation therapy for patients with gynecologic cancers.

Canadian researchers led by Salaheddin M. Mahmud, MD, PhD of the University of Manitoba conducted a study to assess the effectiveness of the quadrivalent human papillomavirus (QHPV) vaccine against cervical dysplasia.

Women are now advised to have fewer screenings over their lifetime.